DNA Relative Valuation
DNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNA is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.00
P/B
Median3y
Median5y
0.00
FCF Yield
Median3y
Median5y
Competitors Valuation Multiple
The average P/S ratio for DNA's competitors is 2.06, providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA) exhibits a P/S ratio of 2.47, which is 19.94% above the industry average. Given its robust revenue growth of 26.16%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Ginkgo Bioworks Holdings Inc (DNA) currently overvalued or undervalued?
What is Ginkgo Bioworks Holdings Inc (DNA) fair value?
How does DNA's valuation metrics compare to the industry average?
What is the current P/B ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Apr 27 2025?
What is the current FCF Yield for Ginkgo Bioworks Holdings Inc (DNA) as of Apr 27 2025?
What is the current Forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA) as of Apr 27 2025?